+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Lycera Corp - logo

Lycera is a biopharmaceutical company that is developing novel small molecule immunomodulatory medicines for the treatment of autoimmune diseases and cancer. The company offers novel oral medicines for diseases such as rheumatoid arthritis, multiple sclerosis, psoriasis, and inflammatory bowel disease. Its lead product is LYC-30937, an ATPase modulator for the treatment of inflammatory bowel disease. Lycera was founded in 2006 and is headquartered in Ann Arbor, Michigan.

Ulcerative Colitis - Pipeline Insight, 2024 - Product Thumbnail Image

Ulcerative Colitis - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 240 Pages
  • Global
From
Psoriasis - Pipeline Insight, 2024 - Product Thumbnail Image

Psoriasis - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 100 Pages
  • Global
From
Systemic Lupus Erythematosus Drug Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type - Product Thumbnail Image

Systemic Lupus Erythematosus Drug Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • October 2023
  • 89 Pages
  • Global
From
Systematic Lupus Erythematosus Drug Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type - Product Thumbnail Image

Systematic Lupus Erythematosus Drug Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • August 2023
  • 111 Pages
  • Global
From
Gastric Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Gastric Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • August 2022
  • 1834 Pages
  • Global
From
Head and Neck Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Head and Neck Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • August 2022
  • 4115 Pages
  • Global
From
Esophageal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Esophageal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • June 2022
  • 844 Pages
  • Global
From
Psoriasis - Pipeline Review, H2 2020 - Product Thumbnail Image

Psoriasis - Pipeline Review, H2 2020

  • Drug Pipelines
  • September 2020
  • 956 Pages
  • Global
From
CAR-T Cell Therapies: Intellectual Property Landscape (Featuring Historical and Contemporary Patent Filing Trends, Prior Art Search Expressions, Patent Valuation Analysis, Patentability, Freedom to Operate, Pockets of Innovation, Existing White Spaces, and Claims Analysis) - Product Thumbnail Image

CAR-T Cell Therapies: Intellectual Property Landscape (Featuring Historical and Contemporary Patent Filing Trends, Prior Art Search Expressions, Patent Valuation Analysis, Patentability, Freedom to Operate, Pockets of Innovation, Existing White Spaces, and Claims Analysis)

  • Report
  • April 2022
  • 116 Pages
  • Global
From
Bladder Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Bladder Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • November 2022
  • 734 Pages
  • Global
From
Ovarian Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Ovarian Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • December 2022
  • 1560 Pages
  • Global
From
Non-Small Cell Lung Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Non-Small Cell Lung Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • December 2022
  • 2271 Pages
  • Global
From
Head And Neck Cancer - Pipeline Review, H2 2020 - Product Thumbnail Image

Head And Neck Cancer - Pipeline Review, H2 2020

  • Drug Pipelines
  • October 2020
  • 3419 Pages
  • Global
From
Esophageal Cancer - Pipeline Review, H2 2020 - Product Thumbnail Image

Esophageal Cancer - Pipeline Review, H2 2020

  • Drug Pipelines
  • September 2020
  • 1584 Pages
  • Global
From
Nuclear Receptor ROR Gamma - Pipeline Review, H2 2019 - Product Thumbnail Image

Nuclear Receptor ROR Gamma - Pipeline Review, H2 2019

  • Drug Pipelines
  • August 2019
  • 119 Pages
  • Global
From
H+ Transporting Two Sector ATPase - Pipeline Review, H1 2020 - Product Thumbnail Image

H+ Transporting Two Sector ATPase - Pipeline Review, H1 2020

  • Drug Pipelines
  • February 2020
  • 47 Pages
  • Global
From
Systemic Lupus Erythematosus Treatment Global Market Report 2024 - Product Thumbnail Image

Systemic Lupus Erythematosus Treatment Global Market Report 2024

  • Report
  • January 2024
  • 200 Pages
  • Global
From
Bladder Cancer - Pipeline Review, H1 2020 - Product Thumbnail Image

Bladder Cancer - Pipeline Review, H1 2020

  • Drug Pipelines
  • June 2020
  • 1855 Pages
  • Global
From
Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H1 2020 - Product Thumbnail Image

Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H1 2020

  • Drug Pipelines
  • June 2020
  • 2815 Pages
  • Global
From
  • 19 Results (Page 1 of 1)
Loading Indicator